ABVC BioPharma (ABVC) News Today $0.75 +0.03 (+4.17%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 2:42 AM | americanbankingnews.comABVC BioPharma (NASDAQ:ABVC) Stock Price Down 7.6%July 19, 2024 | finance.yahoo.comABVC BioPharma's CEO Discusses New Drug Development and AI IntegrationMay 24, 2024 | finance.yahoo.comImmunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50MMay 22, 2024 | finance.yahoo.comABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24MMay 17, 2024 | investorplace.comABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024May 15, 2024 | finance.yahoo.comPromising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50MMay 9, 2024 | finance.yahoo.comCombination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MApril 26, 2024 | finance.yahoo.comABVC BioPharma, Inc. (ABVC)April 18, 2024 | investing.comABVC BioPharma inks licensing deal for cancer drugApril 18, 2024 | finanznachrichten.deABVC BioPharma, Inc.: AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareApril 18, 2024 | globenewswire.comAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareApril 17, 2024 | markets.businessinsider.comABVC BioPharma Enters Licensing Agreement With OncoX For Commercialization Of BLEX 404April 17, 2024 | finance.yahoo.comABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MApril 17, 2024 | globenewswire.comABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MApril 10, 2024 | globenewswire.comABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MMarch 28, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MMarch 27, 2024 | msn.comWhy ABVC BioPharma Stock Is Up TodayMarch 26, 2024 | markets.businessinsider.comABVC Announces Global Licensing Deal With ForSeeCon Eye For VitargusMarch 26, 2024 | globenewswire.comABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MMarch 21, 2024 | finance.yahoo.comAiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsMarch 19, 2024 | ca.finance.yahoo.comABVC BioPharma, Inc. (ABVC) Interactive Stock Chart - Yahoo FinanceMarch 19, 2024 | globenewswire.comABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineMarch 14, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateMarch 14, 2024 | globenewswire.comABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateFebruary 27, 2024 | finance.yahoo.comABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsFebruary 15, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | markets.businessinsider.comABVC Signes Agreement To License Its 'Know-How' To SPIFebruary 15, 2024 | finance.yahoo.comABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | globenewswire.comABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 12, 2024 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)February 12, 2024 | markets.businessinsider.comABVC BioPharma Receives Australian Patent For PDC-1421 For Treatment Of MDDFebruary 12, 2024 | finance.yahoo.comABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)February 9, 2024 | msn.comABVC BioPharma Conducts Private Equity and Warrants SaleFebruary 9, 2024 | msn.comABVC BioPharma Expands Footprint with Strategic Land AcquisitionsJanuary 25, 2024 | benzinga.comLooking Into ABVC BioPharma's Recent Short InterestJanuary 12, 2024 | msn.comABVC BioPharma files to sell 10.4M shares for holdersJanuary 3, 2024 | msn.comWhy Is Plant-Based Medications-Focused ABVC BioPharma Stock Trading Higher Today?January 3, 2024 | markets.businessinsider.comABVC BioPharma Reports Milestone Payment From From AiBtl BioPharma; AiBtl Becomes SubsidiaryJanuary 3, 2024 | marketwatch.comABVC BioPharma Shares Jump 73% After Milestone PaymentJanuary 3, 2024 | msn.comABVC Biopharma and unit receive $460M as first milestone payment; shares jumpDecember 7, 2023 | finance.yahoo.comABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical StudyDecember 5, 2023 | finance.yahoo.comABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical TrialsNovember 21, 2023 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketNovember 21, 2023 | marketwatch.comABVC BioPharma Shares Rise 11% After U.S. Patent for ADHD TreatmentNovember 21, 2023 | finance.yahoo.comABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketNovember 16, 2023 | markets.businessinsider.comABVC BioPharma Enters Into Global LIcensing Agreement With AiBtlNovember 16, 2023 | finance.yahoo.comABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200MNovember 15, 2023 | finanznachrichten.deABVC BioPharma, Inc.: ABVC BioPharma Reports Third Quarter 2023 Financial and Operational ResultsNovember 15, 2023 | msn.comABVC BioPharma GAAP EPS of -$0.82, revenue of $0.02MNovember 15, 2023 | finance.yahoo.comABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Top Stock Unveiled! (Ad)Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. Get Your Free Report ABVC Media Mentions By Week ABVC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABVC News Sentiment▼0.720.62▲Average Medical News Sentiment ABVC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABVC Articles This Week▼31▲ABVC Articles Average Week Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aadi Bioscience News Today Xilio Therapeutics News Today Qilian International Holding Group News Today Immuneering News Today Lipocine News Today Reviva Pharmaceuticals News Today VYNE Therapeutics News Today Equillium News Today Alzamend Neuro News Today Clene News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABVC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
